| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0168-8278(05)80615-4 |
| P698 | PubMed publication ID | 7699225 |
| P2093 | author name string | K E Sherman | |
| M Narkewicz | |||
| P C Pinto | |||
| P2860 | cites work | Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared | Q34477263 |
| Temporal relationships of hepatitis C virus RNA and antibody responses following experimental infection of chimpanzees | Q42983075 | ||
| Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis | Q67553678 | ||
| Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis | Q69662304 | ||
| Effect of Corticosteroids on Suppressor-Cell Activity in Autoimmune and Viral Chronic Active Hepatitis | Q72768073 | ||
| P433 | issue | 6 | |
| P921 | main subject | cyclosporine | Q367700 |
| P304 | page(s) | 1040-1047 | |
| P577 | publication date | 1994-12-01 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. | |
| P478 | volume | 21 |
| Q38054513 | Acute and acute severe (fulminant) autoimmune hepatitis |
| Q38000056 | Advances in the current treatment of autoimmune hepatitis |
| Q55040971 | Autoimmune Hepatitis in the Asia-Pacific Area. |
| Q35906055 | Autoimmune Hepatitis: Clinical Review with Insights into the Purinergic Mechanism of Disease |
| Q86886381 | Autoimmune hepatitis |
| Q86954391 | Autoimmune hepatitis |
| Q34661366 | Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance |
| Q35875273 | Autoimmune hepatitis in Iran: what we know, what we don't know and requirements for better management |
| Q80054493 | Autoimmune hepatitis in children |
| Q42358509 | Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments |
| Q38494826 | Autoimmune hepatitis: an approach to disease understanding and management |
| Q34550808 | Autoimmune hepatitis: current challenges and future prospects |
| Q36231841 | Autoimmune hepatitis: focusing on treatments other than steroids |
| Q33977201 | Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management |
| Q37924059 | Budesonide for the treatment of autoimmune hepatitis |
| Q36376398 | Cost-effectiveness of pharmacotherapy for autoimmune hepatitis |
| Q37503380 | Current and future treatments of autoimmune hepatitis |
| Q34490185 | Current and novel immunosuppressive therapy for autoimmune hepatitis |
| Q43645960 | Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis |
| Q42981851 | Cyclosporine therapy affects aminotransferase activity but not hepatitis C virus RNA levels in chronic hepatitis C. |
| Q37708360 | Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis: Interim Analysis Report of a Randomized Controlled Trial |
| Q92166689 | Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases |
| Q33688293 | Difficult treatment decisions in autoimmune hepatitis |
| Q38051706 | Drug choices in autoimmune hepatitis: part B--Nonsteroids |
| Q78023538 | Drug therapy in the management of type 1 autoimmune hepatitis |
| Q77960457 | Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis |
| Q34936778 | Evolving new therapies of autoimmune hepatitis |
| Q37559266 | Immunosuppressive therapy in immune-mediated liver disease in the non-transplanted patient |
| Q37945752 | Medical management of chronic liver diseases in children (part I): focus on curable or potentially curable diseases |
| Q54034536 | Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. |
| Q73044047 | Mycophenolate mofetil--a new treatment for autoimmune hepatitis? |
| Q41583334 | Prediction of short- and long-term outcome in patients with autoimmune hepatitis |
| Q46408372 | Refractory Autoimmune Hepatitis: Beyond Standard Therapy |
| Q38175465 | Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis |
| Q38027909 | Review article: overlap syndromes and autoimmune liver disease |
| Q26864272 | Review article: the management of autoimmune hepatitis beyond consensus guidelines |
| Q37075975 | Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy |
| Q77754348 | Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate |
| Q92940532 | The Contribution of B Cells in Autoimmune Liver Diseases |
| Q37139335 | The use of budesonide in the treatment of autoimmune hepatitis in Canada |
| Q34149523 | Treatment of autoimmune hepatitis: A review of current and evolving therapies |
| Q34342199 | Treatment of autoimmune liver disease: current and future therapeutic options |
| Q34936764 | Treatment strategies in autoimmune hepatitis |
| Q73185906 | [Autoimmune hepatitis treated with cyclosporin revealed by acute hepatocellular failure] |
| Q82734860 | [Current trend: autoimmune hepatitis] |
Search more.